Globus Medical Inc
NYSE:GMED
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
44.46
84.91
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Globus Medical Inc
Other Long-Term Assets
Globus Medical Inc
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Globus Medical Inc
NYSE:GMED
|
Other Long-Term Assets
$120.4m
|
CAGR 3-Years
48%
|
CAGR 5-Years
41%
|
CAGR 10-Years
61%
|
||
Becton Dickinson and Co
NYSE:BDX
|
Other Long-Term Assets
$2.6B
|
CAGR 3-Years
10%
|
CAGR 5-Years
19%
|
CAGR 10-Years
18%
|
||
Boston Scientific Corp
NYSE:BSX
|
Other Long-Term Assets
$4.5B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
19%
|
CAGR 10-Years
28%
|
||
Stryker Corp
NYSE:SYK
|
Other Long-Term Assets
$3.9B
|
CAGR 3-Years
3%
|
CAGR 5-Years
9%
|
CAGR 10-Years
18%
|
||
Abbott Laboratories
NYSE:ABT
|
Other Long-Term Assets
$7.7B
|
CAGR 3-Years
24%
|
CAGR 5-Years
27%
|
CAGR 10-Years
7%
|
||
Intuitive Surgical Inc
NASDAQ:ISRG
|
Other Long-Term Assets
$1.6B
|
CAGR 3-Years
21%
|
CAGR 5-Years
17%
|
CAGR 10-Years
28%
|
Globus Medical Inc
Glance View
Globus Medical Inc. is a prominent player in the expanding spinal surgery market, leveraging innovation and patient-centric solutions to elevate the standards of care in orthopedic surgery. Founded in 2003, the company has quickly established itself as a leader by developing a comprehensive range of spinal implants and surgical instruments that emphasize minimally invasive techniques. This focus not only enhances patient recovery but also supports surgeons in their pursuit of optimal outcomes. With a robust pipeline of products and a commitment to research and development, Globus Medical aims to maintain its competitive edge by addressing the evolving needs of healthcare professionals and patients alike. For investors, Globus Medical represents a compelling opportunity, as its strong revenue growth and strategic initiatives indicate a promising future. The company has experienced consistent financial performance, underpinned by a growing market demand for spine-related procedures due to aging demographics and an increase in sports-related injuries. Moreover, Globus has pursued strategic acquisitions and collaborations, which have expanded its product offerings and geographical reach. As healthcare systems increasingly prioritize efficiency and patient outcomes, Globus Medical's innovative approach equips it to thrive in an industry ripe with potential, making it an attractive investment choice for those looking to capitalize on the evolving landscape of medical technology.
See Also
What is Globus Medical Inc's Other Long-Term Assets?
Other Long-Term Assets
120.4m
USD
Based on the financial report for Sep 30, 2024, Globus Medical Inc's Other Long-Term Assets amounts to 120.4m USD.
What is Globus Medical Inc's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
61%
Over the last year, the Other Long-Term Assets growth was 60%. The average annual Other Long-Term Assets growth rates for Globus Medical Inc have been 48% over the past three years , 41% over the past five years , and 61% over the past ten years .